Evidence map›Paper›PMID 40191052›Full record

ArticleJournal of contemporary brachytherapy2025

Image-guided high-dose-rate interstitial brachytherapy with custom-made surface applicators for lower lip cancer as monotherapy. Technique, long-term clinical results, and quantitative dose-volume evaluation: A case series.

Hironori Akiyama, Ken Yoshida, Tadayuki Kotsuma, Tadashi Takenaka, Yuji Takaoka, Masataka Nakai, Manabu Kano, Hitoshi Yoshimoto, Kentaro Ozawa, Zoltán Takácsi-Nagy and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of contemporary brachytherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hironori AkiyamaDepartment of Oral Radiology, Osaka Dental University, Otemae, Chuo-Ku, Osaka, Osaka, 540-0008, Japan.
Ken YoshidaDepartment of Radiation Oncology, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Tadayuki KotsumaDepartment of Radiation Oncology, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Tadashi TakenakaDepartment of Radiology, Kyoto Prefectural University of Medicine, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, Kyoto, 602-8566, Japan.
Yuji TakaokaDepartment of Radiation Oncology, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Masataka NakaiDepartment of Radiation Oncology, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Manabu KanoDepartment of Oral and Maxillofacial Surgery, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Hitoshi YoshimotoDepartment of Oral and Maxillofacial Surgery, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Kentaro OzawaDepartment of Dermatology, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Zoltán Takácsi-NagyCentre of Radiotherapy, National Tumor Biology Laboratory, National Institute of Oncology, Department of Oncology, Semmelweis University, Budapest, Hungary.
Koji MasuiDepartment of Radiology, Kyoto Prefectural University of Medicine, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, Kyoto, 602-8566, Japan.
Hideya YamazakiDepartment of Radiology, Kyoto Prefectural University of Medicine, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, Kyoto, 602-8566, Japan.
Yoshiko ArijiDepartment of Oral Radiology, Osaka Dental University, Otemae, Chuo-Ku, Osaka, Osaka, 540-0008, Japan.
Eiichi TanakaDepartment of Radiation Oncology, NHO Osaka National Hospital, Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study showed long-term clinical results and quantitative dose-volume evaluation of image-guided high-dose-rate interstitial brachytherapy (IG HDR-BT) with custom-made surface applicators for lower lip cancer as monotherapy. Material and methods: Patients with localized lower lip cancer, who received IG HDR-BT with custom-made surface applicators as monotherapy at the NHO Osaka National Hospital between February 2012 and January 2015 were enrolled in this study. One to three applicators were implanted interstitially, and two to six were placed on tumor surface. Planning-aimed dose (PAD) was 54 Gy, 48 Gy for a recurrent case, and irradiation was delivered at 6 Gy/fraction, twice a day. Dosimetric goal was to achieve D Results: Six patients (T1 : T2 : T3 = 3 : 2 : 1), including one recurrent case, were enrolled in this study. The CTV was contoured on computed tomography and in two cases, magnetic resonance imaging was used as a reference for contouring. The median follow-up was 69.5 months. The primary tumor was controlled in all cases. No serious late adverse reactions were observed. The median D Conclusions: IG HDR-BT with custom-made surface applicators for lower lip cancer as monotherapy showed an excellent CTV dose and acceptable doses to the mandible, with good long-term clinical results.

Indexed as

custom surface applicatorsimage-guided high-dose-rate interstitial brachytherapylip cancerlong-term clinical resultsquantitative dosimetry

Identifiers

PMID40191052
PMCPMC11966219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.